Item 8.01 Other Events.

On December 15, 2021, Verrica Pharmaceuticals Inc. (the "Company") issued a press release announcing that its resubmitted New Drug Application ("NDA") for VP-102 has been accepted for filing by the U.S. Food and Drug Administration ("FDA") and that the Prescription Drug User Fee Act goal date assigned by the FDA for this NDA is May 24, 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses